Blog

Evaluating the clinical value of a tumor-naïve, methylation-based cell-free DNA assay in resected NSCLC – IASLC

IASLC/LinkedIn

Nov 18, 2024, 17:34

Evaluating the clinical value of a tumor-naïve, methylation-based cell-free DNA assay in resected NSCLC – IASLC

IASLC posted on X about recent paper by Tae Hee Hong et al., titled “Clinical Utility of Tumor-Naïve Presurgical Circulating Tumor DNA Detection in Early-Stage NSCLC” published on Journal of Thoracic Oncology.

Authors: Tae Hee Hong, Soohyun Hwang, Abhijit Dasgupta, Chris Abbosh, Tiffany Hung, Jörg Bredno, Jill Walker, Xiaojin Shi, Tsveta Milenkova, Leora Horn, Joon Young Choi, Ho Yun Lee, Jong Ho Cho, Yong Soo Choi, Young Mog Shim, Shoujie Chai, Kate Rhodes, Manami Roychowdhury-Saha, Darren Hodgson, Hong Kwan Kim, Myung-Ju Ahn

Evaluating the clinical value of a tumor-naïve, methylation-based cell-free DNA assay in resected NSCLC - IASLC

“This study aimed to evaluate the clinical value of a tumor-naïve, methylation-based cell-free DNA assay in a large cohort of patients with resected NSCLC. Read more about the findings here!”

Abhijit Dasgupta cancer Chris Abbosh Darren Hodgson Ho Yun Lee Hong Kwan Kim IASLC Jill Walker Jong Ho Cho Joon Young Choi Jörg Bredno Journal of Thoracic Oncology Kate Rhodes Leora Horn Manami Roychowdhury-Saha Myung-Ju Ahn OncoDaily Oncology Shoujie Chai Soohyun Hwang Tae Hee Hong Tiffany Hung Tsveta Milenkova Xiaojin Shi Yong Soo Choi Young Mog Shim

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

Special Coverage